Dandekar Atul: insider trades.
Dandekar Atul reported 12 non-derivative transactions on 5 SEC ownership filings in Q3 2026: 0 open-market purchases and 8 sales ($791K), across 1 company.
- Transactions
- 12
- Purchases (P)
- 0
- Sales (S)
- 8
- Companies
- 1
- Name as filed
- Dandekar Atul
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | Officer · CSBO | 12 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-03 | Maze Therapeutics, Inc. | S | 3,207 | $26.01 | 32,352 | Form 4 |
| 2026-09-03 | Maze Therapeutics, Inc. | S | 36 | $25.81 | 32,316 | Form 4 |
| 2026-09-02 | Maze Therapeutics, Inc. | S | 2,800 | $26.38 | 35,950 | Form 4 |
| 2026-09-02 | Maze Therapeutics, Inc. | S | 391 | $27.12 | 35,559 | Form 4 |
| 2026-09-01 | Maze Therapeutics, Inc. | M | 12,500 | $0 | 38,750 | Form 4 |
| 2026-08-28 | Maze Therapeutics, Inc. | S | 7,500 | $27.58 | 26,250 | Form 4 |
| 2026-08-28 | Maze Therapeutics, Inc. | M | 7,500 | $10.42 | 33,750 | Form 4 |
| 2026-07-29 | Maze Therapeutics, Inc. | M | 7,500 | $10.42 | 33,750 | Form 4 |
| 2026-07-29 | Maze Therapeutics, Inc. | S | 400 | $27.89 | 26,250 | Form 4 |
| 2026-07-29 | Maze Therapeutics, Inc. | S | 7,100 | $27.31 | 26,650 | Form 4 |
| 2026-06-29 | Maze Therapeutics, Inc. | S | 7,500 | $28.02 | 26,250 | Form 4 |
| 2026-06-29 | Maze Therapeutics, Inc. | M | 7,500 | $10.42 | 33,750 | Form 4 |
Questions
What stock did Dandekar Atul buy or sell?
Dandekar Atul reported 12 non-derivative transactions on 5 SEC ownership filings in Q3 2026: 0 open-market purchases and 8 sales ($791K), across 1 company.
Is Dandekar Atul the same person as other filers with this name?
This page covers SEC CIK 2050167 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/dandekar-atul-2050167.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.